Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A study conducted by Takeda Pharmaceuticals has indicated that its diabetes drug Actos significantly reduces the risk of serious cardiovascular problems in diabetic patients.
Subscribe to our email newsletter
In the study of more than 5000 patients, the drug was shown to reduce the risk of heart attacks, strokes and death by 16% in high-risk patients with type 2 diabetes, the most common form of the disorder.
The drug was given to patients in conjunction with their standard treatments for diabetes. These standard treatments included anti-hypertensives such as ACE inhibitors and beta blockers; glucose-lowering agents such as metformin, sulfonylureas and insulin; antiplatelet drugs such as aspirin, and lipid- modifying medicines such as statins and fibrates.
“The PROactive study is the first in the world to prospectively show that a specific oral glucose lowering medication, namely pioglitazone, can significantly improve cardiovascular outcomes by helping to delay or reduce heart attacks, strokes and death in high-risk patients,” said Dr John Dormandy, professor of vascular sciences at St George’s Hospital, London, UK, and chairman of the study steering committee.
Results from the study were presented at the 41st meeting of the European Association for the Study of Diabetes.